Non-Hodgkins Lymphoma Cancer Studies Currently Recruiting Participants at the University of Chicago Comprehensive Cancer Center

Study Number Title
10-064-B Molecular characterization of hematopoietic malignancies
10-558-B Long Term Database Collection for Lymphoma
13-0119 CALGB 51101: A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy For Newly Dianosed Primary CNS B-Cell Lymphoma
IRB14-0038 A Phase II Study of IPI-145 in Subjects with Refractory Indolent Non-Hodgkin Lympohoma
IRB13-1105 NCI 9426: A Phase I Study of Ibrutinib (PCI-32765) in Combination with Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
IRB13-1297 Lymphoma Program Biobank
IRB13-1413 A Phase I/II Trial of Brentuximab Vedotin plus Rituximab as Frontline Therapy for Patients with CD30+ and/or EBV+ Lymphomas
IRB14-0081 Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
IRB14-0471 An Open Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (asparaginase Erwinia chrysanthemi)/ Erwinase® (crisantaspase) Administered Following Hypersensitivity to E. Coli Asparaginase in Young Adults with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
IRB14-1042 A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.